Digital devices useful in visual rehabilitation

Article

Digital devices may be used as a visual rehabilitation technique for low-vision AMD patients, according to a paper featured in the journal Eye.

Digital devices may be used as a visual rehabilitation technique for low-vision AMD patients, according to a paper featured in the journal Eye.

An investigation led by Dr K. Gill, Department of Ophthalmology, University of Western Ontario, London, Ontario, Canada, included 27 patients in the study. All patients had stable wet AMD in one or both eyes and were assessed for reading speeds on both digital readers and standard paper text.

The reading speed was calculated as words per minute and each patient completed the visual analogue scale after reading each passage. The patients read font sizes ranged from newsprint to large print books and then read from digital devices for comparison.

In conclusion, patients read faster on the Apple iPad with text sizes of 24 or more, compared to paper. Patients claimed the digital device has the best clarity but the print paper is the easiest to use.

Devices with larger display screens and high contrast ratios are beneficial to AMD patients who require larger texts for reading.

The abstract can be found here.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.